Noona announces dream team of scientific advisors

Noona has teamed up with its first two front row Scientific Advisors. Professor George Sledge is Chief of Division of Oncology at Stanford University Medical Center. Professor Ethan Basch is Director of the Cancer Outcomes Research Program, and Professor at UNC-Chapel Hill Department of Medicine.

”This is the dream come true for Noona. Working with Professor Sledge and Professor Basch will give us a tremendous competitive advantage – really taking us to the next level. Our shared mission is to build a game-changing mobile service for monitoring cancer care and follow-up. Therefore we are extending our cooperation to include both R&D and clinical research. The goal is to bring patient reported outcomes into the clinical workflow in order to decrease severe symptoms, increase satisfaction, save clinic resources and avoid emergency room admissions.” says Jani Ahonala, CEO of Noona Healthcare.

Disrupting clinical trials in Oncology?

In the near future Noona will be able to offer pharma companies and healthcare payers a unique tool to collect and analyze health outcomes of individual cancer treatments. There are currently hundreds of new cancer molecules in late stage trials. Noona’s unique user experience and strong patient engagement offer a novel opportunity to collect real world data quickly and cost-efficiently in all cancer types. So far, over 70 % of patients have started using Noona upon request. More than 90 % of these patients use Noona in ways that allow us to retrieve scientifically valuable data.

”Our vision is to build the world’s biggest data base on cancer patients’ wellbeing and symptoms by 2020. And the true beauty of it all,” Ahonala concludes, “is that every data point is produced by a patient.”

 

GEORGE W. SLEDGE JR., M.D.
Professor, and Chief, Division of Oncology, Stanford University Medical Center.
Dr. George W. Sledge, Jr., M.D. is Professor and Chief of Medical Oncology at Stanford University Medical Center. Dr. Sledge served as a Ballve-Lantero Professor of Oncology of Medicine and Pathology of Indiana University School of Medicine. He served as Co-Director of the breast cancer program at the Indiana University Cancer Center, where he was a Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. Dr. Sledge specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He served as a Professor of Indiana University Cancer Center Breast Cancer Program. He has also served as the chair of ASCO’s Education Committee, as a member of the Department of Defense Breast Cancer Research Program’s Integration Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee (ODAC), and as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project. Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’. He holds a B.A. from the University of Wisconsin and an M.D. from Tulane University.

ETHAN BASCH, M.D., MSc
UNC Lineberger Comprehensive Cancer Center member, Director of Cancer Outcomes Research Program, and Professor in UNC-Chapel Hill Department of Medicine in the Division of Hematology and Oncology.
Dr. Basch is a medical oncologist and health services researcher.  His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research. He  is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute.  He leads an ongoing NCI initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.

October 19th 2017

Emmanuel Blin named Chairman of the Board at Noona Healthcare

Noona Healthcare has appointed Emmanuel Blin to the position of Chairman of the Board as of 18.10.2017. He will work closely with Noona management and board members to impleme...

Read more

August 31st 2017

Noona hosted IxDA designer network event

We had the honor to host the designer network IxDA Helsinki’s monthly meet-up in August (http://ixda.fi/). We had a full house of designers listening talks and discussing around the subject...

Read more

September 08th 2017

Meet Noona at ESMO 2017

We are joining ESMO 2017 in Madrid. Please to come to visit us if you happen to join the conference. You can find our location from the map below.

Our bar is serving fresh smoothies, Finnish chocol...

Read more

December 12th 2016

Noona as one of the world’s most promising start-ups by Accenture

Noona was accepted to take part Accenture’s HealthTech Innovation Challenge Finals. Noona was chosen from among almost 600 start-up applicants from around the world.

”Many have...

Read more

November 23rd 2016

Noona Healthcare Raises €1,5 Million in Seed Funding – Brings Finnish Cancer Care Expertise to the Global Market in Digital Format

HELSINKI, November 22nd 2016 – Noona Healthcare, a cloud-based oncology platform for patient-reported outcomes, announced the completion of a €1.5 million seed funding round led b...

Read more

June 14th 2016

Noona among the 20 most promising European digital health companies

Noona was chosen as one of the 20 most promising digital health companies in Europe, out of 320 hand-picked candidates evaluated by the Healthtech...

Read more